TIGIT is upregulated on T cells in cancer.
Clone TG1 allows the identification of TIGIT positive T-cells in standard FFPE human tumors. The new clone TG2 shows higher staining intensity.
CD112R inhibits T cell mediated signals.
Clone R12 is ideally suited for multiplexed IHC studies of PVRIG/CD112R. R12 has been validated on large quantities of normal and tumor tissues.
ONCOdianova's vision is to provide the best antibodies against cancer immunology checkpoint biomarkers for combined use in multiplex IHC panels.
CD112R (red) x FOXP3 (green)
Clone FX3 detects FOXP3 positive TILs in FFPE human tumors.
Clone TC8 detects tumor infiltrating lymphocytes (TILs).
Clone KK3, validated for CD73 detection in FFPE tissue.
Our antibodies have been tested on many different tumor and normal tissues.
Our clones have been validated by pathologists from routine diagnostic laboratories.
ONCOdianova is an antibody manfucaturing network linking antibody development to
Explore the new anti-TIGIT clone TG2 now with higher staining intensity.
ONCOdianova is an antibody manufacturing network. The purpose is to manufacture excellent antibodies with optimized signal-to-noise ratio. Such optimized antibodies are especially needed in multicolor fluorescence based immunohistochemistry if many different antibodies are simultaneously analyzed. The mission of ONCOdianova is to develop a portfolio of “best in class antibodies” for proteins that are potentially relevant for triggering treatment decisions or for diagnostic pathology.
Our idea is to integrate immunohistochemistry as early as possible in the hybridoma screening procedure and thereby expand the classical ELISA screen by histopathological expertise at an early stage of FFPE antibody development.
We use our strong network for histopathological validation of new targets in human tissues. This expands our expertise to develop new test systems for novel targets. For cancer immunology targets we put a focus on tumor infiltrating lymphocytes.
Multiplex Assay technology develops fast and depends on the availability of reliable antibody reagents. Our vision is to provide the best cancer immunology marker antibodies for combined use to improve the understanding of patient subpopulations.
Our objective is to potentially develop multiple clones for the same target by approaching one target at diverse immunogenic sites. We are able to reference mapped epitopes and open for beta testing opportunities with pharmaceutical partners.
GET IN TOUCH
We are keen to learn from our clients and actively respond to the aims and interests of our audience. If you think we can do even more, we are always happy to discuss your needs.
Whether you want to find out more information, give us feedback or just ask us a question, please contact us via the contact details or using the online form to the right.
ONCOdianova is a network of experts for the development of excellent antibodies (best-in-class antibodies) for tissue-based detection of tumor markers. The focus is on new biomarkers for tumor immunology checkpoints, as they may be of diagnostic and prognostic significance in the future. ONCOdianova aims to develop antibodies with an optimized signal-to-noise ratio for use in multicolored fluorescence-based IHC (Multiplex immunohistochemistry).
The following antibody highlights from ONCOdianova have already developed relevance for clinical histopathology:
1. TIGIT is one of the most important checkpoint markers for the development of new immunotherapies against cancer. With antibody clone TG1, TIGIT could for the first time be detected immunohistochemically in tumor tissue.
2. PVRIG / CD112R plays an important role in the development of effective combination therapies with PD1 and TIGIT. The IHC detection of PVRIG in tumor tissues so far is only possible with clone R12.
3. Antibody clone CAL2 is used for the detection of all types of Calreticulin mutations in myeloproliferative neoplasms (MPN) and reliably differentiates CALRmutated ET and PMF from PV.
Our strong feedback from laboratories applying the new ONCOdianova antibodies against CD112R, TIGIT and CALRmut shows that they are perceived as innovative tools for immunohistochemistry, because they allow new approaches for tissue based studies of important biomarkers.